• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全新辅助治疗会影响全直肠系膜切除术中的手术精准度吗?一项针对专家外科医生经验的全国性调查。

Does Total Neoadjuvant Therapy Impact Surgical Precision in Total Mesorectal Excision? A Nationwide Survey of the Experiences of Expert Surgeons.

作者信息

Jäger Tarkan, Zitt Matthias, Riss Stefan, Presl Jaroslav, Schredl Philipp, Neureiter Daniel, Ramspott Jan Philipp, Tschann Peter, Brunner Walter, Nehoda Hermann, Pressl Gerd, Rohregger Klemens, Sucher Robert, Jenic Gerhard, Heuberger Andreas, Kafka-Ritsch Reinhold, Tschmelitsch Jörg, Schabl Lukas, Dornauer Isabella, Dermuth Florentina, Rokitte Karin, Singhartinger Franz, Holzinger Josef, Königsrainer Ingmar, Emmanuel Klaus, Aigner Felix

机构信息

Department of Surgery, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.

Department of Surgery, Dornbirn General Hospital, 6850 Dornbirn, Austria.

出版信息

Cancers (Basel). 2025 Jan 17;17(2):283. doi: 10.3390/cancers17020283.

DOI:10.3390/cancers17020283
PMID:39858065
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11763819/
Abstract

BACKGROUND

The treatment of locally advanced rectal cancer (LARC) has steadily progressed over the past four decades, with recent focus shifting towards total neoadjuvant therapy (TNT). This survey aims to elucidate the perceived surgical challenges faced by Austrian colorectal surgeons performing total mesorectal excision (TME), focusing on the increased complexity and surgical difficulty introduced by intensified treatment regimens.

METHODS

A comprehensive survey was conducted among Austrian colorectal surgeons to explore various aspects of managing and performing TME following TNT. The survey included questions on the general management of LARC within their institutions and utilized a five-point Likert scale to assess the respondents' perceptions and experiences regarding surgical precision and post-operative morbidity associated with TNT.

RESULTS

A total of 31 surgeons (54% response rate) completed the survey. Regarding multidisciplinary therapy preferences, 56% of respondents preferred conventional neoadjuvant therapy regimens, with 32% favoring chemoradiotherapy and 24% opting for short-course radiotherapy, while 31% chose TNT. The majority of respondents (65%) reported quality differences in tissue dissection during TME following TNT, with 57% experiencing difficulties in identifying tissue planes and 47% noting increased tissue fragility. Increased bleeding was reported by 32% of respondents. In cases of regrowth after a watch-and-wait approach, 64% observed quality changes in tissue dissection, and 47% noted tissue fragility.

CONCLUSIONS

The survey results indicate that TNT impairs surgical precision due to changes in tissue quality and challenges in identifying surgical planes. Given the critical importance of surgical precision in achieving low local recurrence rates in mid-to-low LARC, these challenges could significantly impact patient outcomes. Further prospective studies are required to elucidate the extent of these effects.

摘要

背景

在过去的四十年里,局部晚期直肠癌(LARC)的治疗取得了稳步进展,最近的重点转向了全新辅助治疗(TNT)。本调查旨在阐明奥地利结直肠外科医生在进行全直肠系膜切除术(TME)时所面临的手术挑战,重点关注强化治疗方案带来的复杂性增加和手术难度。

方法

对奥地利结直肠外科医生进行了一项全面调查,以探讨TNT后TME的管理和实施的各个方面。该调查包括关于其所在机构内LARC的一般管理问题,并使用五点李克特量表来评估受访者对与TNT相关的手术精度和术后发病率的看法和经验。

结果

共有31名外科医生(回复率54%)完成了调查。关于多学科治疗偏好,56%的受访者更喜欢传统的新辅助治疗方案,32%的人倾向于放化疗,24%的人选择短程放疗,而31%的人选择TNT。大多数受访者(65%)报告了TNT后TME期间组织解剖质量的差异,57%的人在识别组织层面时遇到困难,47%的人指出组织脆性增加。32%的受访者报告出血增加。在观察等待方法后的复发病例中,64%的人观察到组织解剖质量的变化,47%的人指出组织脆性。

结论

调查结果表明,由于组织质量的变化和识别手术层面的挑战,TNT会损害手术精度。鉴于手术精度在中低位LARC实现低局部复发率方面的至关重要性,这些挑战可能会显著影响患者的预后。需要进一步的前瞻性研究来阐明这些影响的程度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/43b76ca578c4/cancers-17-00283-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/b81c30f89f2b/cancers-17-00283-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/6f74754c1ffb/cancers-17-00283-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/576a931074b7/cancers-17-00283-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/4d3a93450fc5/cancers-17-00283-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/d18da4197199/cancers-17-00283-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/07a3400be6aa/cancers-17-00283-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/c0d132a554c6/cancers-17-00283-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/c344616a232a/cancers-17-00283-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/b7aa44ef3b59/cancers-17-00283-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/33eb6a81707c/cancers-17-00283-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/4bf2d7012092/cancers-17-00283-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/c58de5d039bc/cancers-17-00283-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/43b76ca578c4/cancers-17-00283-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/b81c30f89f2b/cancers-17-00283-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/6f74754c1ffb/cancers-17-00283-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/576a931074b7/cancers-17-00283-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/4d3a93450fc5/cancers-17-00283-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/d18da4197199/cancers-17-00283-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/07a3400be6aa/cancers-17-00283-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/c0d132a554c6/cancers-17-00283-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/c344616a232a/cancers-17-00283-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/b7aa44ef3b59/cancers-17-00283-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/33eb6a81707c/cancers-17-00283-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/4bf2d7012092/cancers-17-00283-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/c58de5d039bc/cancers-17-00283-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7146/11763819/43b76ca578c4/cancers-17-00283-g013.jpg

相似文献

1
Does Total Neoadjuvant Therapy Impact Surgical Precision in Total Mesorectal Excision? A Nationwide Survey of the Experiences of Expert Surgeons.全新辅助治疗会影响全直肠系膜切除术中的手术精准度吗?一项针对专家外科医生经验的全国性调查。
Cancers (Basel). 2025 Jan 17;17(2):283. doi: 10.3390/cancers17020283.
2
A contemporary assessment of total neoadjuvant therapy (TNT) protocols for locally advanced rectal cancer: adoption and expert perspectives at German Cancer Society (DKG)-certified colorectal cancer centers.当代局部晚期直肠癌新辅助治疗(TNT)方案评估:德国癌症协会(DKG)认证结直肠肿瘤中心的采用情况和专家观点。
J Cancer Res Clin Oncol. 2023 Oct;149(13):12591-12596. doi: 10.1007/s00432-023-05139-6. Epub 2023 Jul 12.
3
The impact of short-course total neoadjuvant therapy, long-course chemoradiotherapy, and upfront surgery on the technical difficulty of total mesorectal excision: an observational study with an intraoperative perspective.短程全新辅助治疗、长程放化疗及 upfront 手术对全直肠系膜切除技术难度的影响:一项术中视角的观察性研究
Ann Coloproctol. 2024 Oct;40(5):451-458. doi: 10.3393/ac.2023.00899.0128. Epub 2024 Sep 19.
4
Surgical and short-term oncological safety of total neoadjuvant therapy in high-risk locally advanced rectal cancer.全新辅助治疗高危局部进展期直肠癌的手术和短期肿瘤学安全性。
ANZ J Surg. 2024 Feb;94(1-2):175-180. doi: 10.1111/ans.18739. Epub 2023 Oct 17.
5
[Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].[局部晚期高危直肠癌患者新辅助综合治疗的疗效与安全性分析]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Apr 25;22(4):349-356. doi: 10.3760/cma.j.issn.1671-0274.2019.04.007.
6
[Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].巩固性新辅助治疗或全新辅助治疗后低位直肠癌的保直肠手术:初步报告
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):281-288. doi: 10.3760/cma.j.cn.441530-20200228-00096.
7
Surgical Outcomes in Total Neoadjuvant Therapy for Rectal Cancer Versus Standard Long-course Chemoradiation: A Systematic Review and Meta-analysis of Randomized Controlled Trials.直肠癌全新辅助治疗与标准长程放化疗的手术结果:一项随机对照试验的系统评价和荟萃分析
Ann Surg. 2024 Apr 1;279(4):620-630. doi: 10.1097/SLA.0000000000006161. Epub 2023 Nov 27.
8
["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].直肠癌新辅助治疗后的“观察与等待”策略:中国外科医生的认知、态度及治疗选择现状调查
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Jun 25;22(6):550-559. doi: 10.3760/cma.j.issn.1671-0274.2019.06.008.
9
Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials.新辅助治疗后接受全直肠系膜切除术或选择性观察等待治疗的患者生存率:CAO/ARO/AIO-12和OPRA随机II期试验的汇总分析
Ann Oncol. 2025 May;36(5):543-547. doi: 10.1016/j.annonc.2025.01.006. Epub 2025 Jan 21.
10
[Reassessment of practice of Chinese surgeons since introduction of the watch and wait strategy after neoadjuvant therapy for rectal cancer].[新辅助治疗后直肠癌采用观察等待策略后中国外科医生的实践再评估]
Zhonghua Wei Chang Wai Ke Za Zhi. 2024 Apr 25;27(4):383-394. doi: 10.3760/cma.j.cn441530-20240108-00011.

本文引用的文献

1
Total Neoadjuvant Therapy for Rectal Cancer: Which Regimens to Use?直肠癌的全新辅助治疗:采用哪些方案?
Cancers (Basel). 2024 May 31;16(11):2093. doi: 10.3390/cancers16112093.
2
Neoadjuvant treatment of colorectal cancer: comprehensive review.结直肠癌的新辅助治疗:全面综述。
BJS Open. 2024 May 8;8(3). doi: 10.1093/bjsopen/zrae038.
3
Surgical Outcomes after Radiotherapy in Rectal Cancer.直肠癌放疗后的手术结果
Cancers (Basel). 2024 Apr 18;16(8):1539. doi: 10.3390/cancers16081539.
4
Late Local Recurrence after Neoadjuvant Therapy and Radical Resection for Locally Advanced Rectal Cancer.新辅助治疗和根治性切除术后局部晚期直肠癌的晚期局部复发
Cancers (Basel). 2024 Jan 20;16(2):448. doi: 10.3390/cancers16020448.
5
Total neoadjuvant therapy in rectal cancer: the evidence and expectations.直肠癌的新辅助治疗:证据与展望。
Crit Rev Oncol Hematol. 2023 Dec;192:104196. doi: 10.1016/j.critrevonc.2023.104196. Epub 2023 Nov 4.
6
Time Interval Between the End of Neoadjuvant Therapy and Elective Resection of Locally Advanced Rectal Cancer in the CRONOS Study.CRONOS 研究中局部晚期直肠癌新辅助治疗结束与择期切除之间的时间间隔。
JAMA Surg. 2023 Sep 1;158(9):910-919. doi: 10.1001/jamasurg.2023.2521.
7
Selecting a TNT Schedule in Locally Advanced Rectal Cancer: Can We Predict Who Actually Benefits?选择局部晚期直肠癌的短程放疗方案:我们能否预测谁真正能从中获益?
Cancers (Basel). 2023 Apr 30;15(9):2567. doi: 10.3390/cancers15092567.
8
Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial.短程放疗联合化疗和手术与长程放化疗和手术的局部区域失败比较:RAPIDO 试验的 5 年随访。
Ann Surg. 2023 Oct 1;278(4):e766-e772. doi: 10.1097/SLA.0000000000005799. Epub 2023 Jan 20.
9
Impact of Total Neoadjuvant Therapy on Postoperative Outcomes After Proctectomy for Rectal Cancer.全直肠系膜新辅助治疗对直肠癌直肠切除术后结局的影响。
Dis Colon Rectum. 2023 Jul 1;66(7):1022-1028. doi: 10.1097/DCR.0000000000002555. Epub 2022 Oct 14.
10
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.直肠癌患者接受全新辅助治疗后的器官保存。
J Clin Oncol. 2022 Aug 10;40(23):2546-2556. doi: 10.1200/JCO.22.00032. Epub 2022 Apr 28.